Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma

Doxorubicin and Etoposide in the Treatment of Advanced Measurable Breast Cancer

“…We also applied very strict criteria for dose reduction in these patients, leading to dose reduction in the majority of them. These factors might be in part responsible for the relatively lower response rate observed in this study with respect to other com binations containing doxorubicin [2,3], The 42% re sponse rate observed with this combination chemo therapy, however, is similar to that obtained by other authors [18,19]. Whether doxorubicin alone can ob tain the same results as the combination should be answered by a randomized trial.…”

“…We employed doxorubicin in combination with VP 16, based on some prior encouraging experiences, reporting 13-40% response rates in patients variously pretreated [18][19][20]. We entered only patients without prior chemotherapy or with mild pretreatment (31% of patients were pretreated with CMF for metastatic disease); moreover, we studied only patients who had measurable disease, in order to avoid unclear efficacy assessment due to poor evaluability of some lesions (e. g. bone involvement).…”

“…Some previous studies [18][19][20] shewed encouraging activity using VP16 in combination with doxorubicin in patients with refractory breast carcinoma. We test ed the antitumor activity of the combination VP 16-doxorubicin in patients with advanced breast car cinoma and measurable disease.…”